Letter of Response Regarding Adrenal SABR to the Article Published in the March 2024 Journal Publication: Prospective Longitudinal Assessment of Quality of Life after Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial by Cruz-Lim et al.